SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ImmunoGen, Inc. (IMGN) , forward earnings yield 2.74%.
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($14.79, 52.6%).
- Forward P/E 36.5
- Analyst consensus target $14.79 (-52.6% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 33/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IMGN
Valuation Multiples
P/E (TTM)0.0
Forward P/E36.5
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio72.83
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.88
Forward EPS (Est.)$0.86
Book Value / Share$0.00
Revenue / Share$0.43
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield2.74%
Dividend Yield0.00%
Analyst Target$14.79 (-52.6%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.83 |
$59.9M |
$-71.36M |
-119.1% |
| 2014 |
$-0.71 |
$85.54M |
$-60.74M |
-71% |
| 2015 |
$-1.65 |
$60M |
$-143.66M |
-239.4% |
| 2016 |
$-1.80 |
$48.63M |
$-156.73M |
-322.3% |
| 2017 |
$-0.98 |
$115.45M |
$-96.01M |
-83.2% |
| 2018 |
$-1.20 |
$53.82M |
$-167.87M |
-311.9% |
| 2019 |
$-0.82 |
$82.27M |
$-122.09M |
-148.4% |
| 2020 |
$-0.38 |
$132.3M |
$-66.68M |
-50.4% |
| 2021 |
$-1.08 |
$69.86M |
$-139.3M |
-199.4% |
| 2022 |
$-0.88 |
$108.78M |
$-222.93M |
-204.9% |
